



RESEARCH UPDATE

Dave Storms, CFA

Dave@stonegateinc.com

214-987-4121

Market Statistics in CAD

Price	\$ 2.29
52 week Range	\$1.50 - \$5.00
Daily Vol (3-mo. average)	6,375
Market Cap (M)	\$ 29.1
Enterprise Value (M)	\$ 47.1
Shares Outstanding: (M)	12.7
Float (M)	7.6

Financial Summary in CAD

Cash (M)	\$ 7.3
Cash/Share	\$ 0.57
Debt (M)	\$ 22.3
Equity (M)	\$ 3.6
Equity/Share	\$ 0.28


FYE: Mar	2025	2026E	2027E
----------	------	-------	-------

(all figures in M, except per share information)

Rev	\$ 0.4	\$ 3.2	\$ 14.0
Chng%	107%	739%	338%

EBITDA	\$ (7.7)	\$ (6.3)	\$ 3.5
Net Income	\$ (8.3)	\$ (7.8)	\$ 4.5
EPS	\$ (1.06)	\$ (0.07)	\$ 0.03

EV/Revenue	50.7x	27.0x	4.4x
EV/EBITDA	N/A	N/A	30.8x
P/E	N/A	-32.3x	73.1x



COMPANY DESCRIPTION

Burcon NutraScience Corporation is a global leader in innovative technologies for the large-scale production of high-quality, cost-effective plant-based proteins and ingredients for use in the global food and beverage industries. Burcon is a leader in the development of plant-based proteins amassing over 100 issued patents and over 80 additional patent applications. Burcon's portfolio includes pea, canola, soy, sunflower, hemp, and upcycled based proteins. Burcon is headquartered in Vancouver, BC and began trading on the TSX in 1999 under the ticker symbol "BU".

BURCON NUTRASCIENCE CORPORATION (TSX: BU)

Company Updates

Pea & Fava Protein Commercialization: In 2Q26, Burcon advanced commercialization across multiple proteins at the Galesburg facility, achieving first commercial production and sales of Puratein® C canola protein and first commercial production of FavaPro™ fava protein, while continuing to scale Peazazz® C pea protein. Subsequent to quarter-end, the Company received more than \$500,000 in commercial sales orders and recorded the first commercial sale of FavaPro, signaling growing demand as customers complete evaluations and move to purchase orders. This operational flexibility positions the Company to meet evolving customer needs quickly and with consistent quality.

Commercial Engagement and Product Pipeline: Customer engagement continued to broaden, with 200 plus active projects progressing through late-stage evaluations and a diverse mix of end-market applications across food, beverage, and lifestyle nutrition. The Company's 2Q26 execution included record production activity and successful trade-show outreach, reinforcing momentum to convert pipeline activity into recurring orders and expand shipments as production scales.

Financing Makes Room for Growth: During and subsequent to the quarter, BU announced a non-brokered private placement of up to \$4.0M in unsecured convertible debentures bearing 15% annual interest (payable at maturity) with a 48-month term and a conversion price of \$2.27 per share, including a conditional accelerated prepayment or conversion feature if the share price trades above \$4.54 for 14 consecutive trading days. Insiders committed to a minimum of \$2.0M. The Company also executed a \$700,000 short-term unsecured loan with an entity related to a director at 12% interest to bridge to the debenture closing and extended the maturity of the second tranche of its senior secured loan to December 2026. Proceeds are intended for inventory, labor, production capability, planning future infrastructure, general corporate purposes, and repayment of the bridge loan.

Financial Overview: In 2Q26, Burcon generated \$0.36M in revenues, a 783% increase over the prior year period, driven by initial protein sales and contract manufacturing, with year-to-date revenue of ~\$0.7M. The quarter's net loss was \$3.59M, or \$0.28 per share, reflecting \$2.1M in COGS that included startup and commissioning costs; operating focus shifted toward commercialization, with R&D and G&A expenses down 67% and 17% respectively, from the prior year period. The Company ended 2Q26 with \$1.8M in cash and a working capital deficit of \$8.2M; subsequent actions included receipt of over \$500,000 in orders, the announced convertible debenture offering, the \$700,000 director loan, and the senior secured loan maturity extension. Management reaffirmed its CY25 revenue target of \$1–3M and its CY26 outlook for \$10 million plus revenue and a path to positive cash flow.

Valuation: We use a DCF Model to frame our valuation of BU. Our DCF analysis relies on a range of discount rates between 10.50% and 11.00% with a midpoint of 10.75%, which we believe accurately accounts for the size and relative illiquidity of BU. This arrives at a valuation range of \$20.29 to \$25.66 with a mid-point of \$22.61.

Business Overview

Burcon NutraScience Corporation (“BU”, “Burcon”, or “the Company”) is a global leader in innovative technologies for the large-scale production of high-quality, cost-effective plant-based proteins and ingredients for use in the global food and beverage industries. Burcon is a leader in the development of plant-based proteins amassing over 100 issued patents and over 80 additional patent applications. Burcon’s portfolio includes pea, canola, soy, sunflower, hemp, and upcycled based proteins, for a combined TAM of ~\$40.0B. Each of these proteins have unique nutritional and functional value that can be used in a variety of consumable products including dairy foods, coffee creamers/whiteners, protein bars, vegetarian and vegan foods, ready-to-drink beverages, baked goods, and meat substitutes to name a few. Burcon is headquartered in Vancouver, BC and began trading on the Toronto Stock Exchange in 1999 under the ticker symbol “BU”.

Exhibit 1: Burcon Protein Portfolio Overview



Source: Company Presentation

Given Burcon’s 20+ year history of plant protein innovation we believe that demand in the market is beginning to catch up to Burcon’s offerings. As the global demand for plant-based proteins continues, some protein sources stand to benefit more than others. We expect the Company to continue to innovate and capture new revenue streams in-line with this increasing demand through its Burcon 2.0 initiative. Burcon 2.0 is expected to be highlighted by control over the manufacturing process, a renewed focus on commercial validation, leading to additional revenue streams that go beyond the traditional royalty model. We expect this to be spearheaded by the innovation in hempseed protein, as well as Canola protein, which is expected to scale in 2024 now that it has passed the initial proof point and initial commercialization, completed in 2Q25. We note the recent milestone of gaining control over the manufacturing process as the Company entered a strategic partnership to acquire a production facility.

Exhibit 2: Burcon 2.0 Strategic Imperatives



Source: Company Presentation

Product Lines

Burcon has a long history of developing plant protein ingredients as evidenced by its extensive patent portfolio. The Company differentiates its plant-based proteins via flavor, solubility, nutrition, and purity. With its extensive experience, the Company has demonstrated its ability to consistently develop neutral-flavored, highly soluble ingredients with high protein content.

Burcon's portfolio of products spans plant-based proteins from:

Soy – Soybean based proteins were the Company's first plant-based product. Soy proteins are currently in the test market phase of Burcon 2.0

as the Company works to qualify new markets and revenue streams to determine the best value capture model going forward. Burcon forecasts its opportunity in the soy market to be between \$79.0M to \$165.0M in USD, with an expected TAM of \$4.5B and 4.6% market CAGR.


Pea – Burcon's pea protein is one of the Company's legacy products that has been proven at commercial scale over the last 15 years. As of 3Q25, Burcon successfully launched their next-generation pea protein; Peazazz®. One of the prime benefits to pea proteins is that they can be produced from non-GMO sources and are not considered a major allergen. Pea proteins have reached commercial production, a key operational milestone for Burcon as it works to scale up and capture additional revenue streams. Burcon forecasts its opportunity in the pea market to be between \$70.0M to \$116.0M in USD, with an expected TAM of \$2.9B and 11.9% market CAGR.

Canola – Canola based proteins are produced from the byproducts of canola oil production. Canola meal is an abundant and inexpensive product that is currently sold mostly as animal feed but is approximately 35% protein. The Company has relaunched this product to positive feedback and is expected to begin commercial production and sales in 2H24. Canola proteins are currently in the test market phase of Burcon 2.0 as the Company has shortened the product development cycle and validated customer demand. In 3Q25, Burcon announced a collaboration with Puratos to pioneer new canola protein applications. Additionally, the Company launched Puratein® canola protein for egg replacement applications; and completed two separate contract research projects. Burcon forecasts its opportunity in the canola market to be between \$58.0M to \$96.0M in USD, with an expected TAM of \$2.2B and 7.8% market CAGR.

Sunflower – Sunflower based proteins are past the Company's pilot-scale. Sunflower proteins are attractive in part due to the wide availability of raw materials as well as the upcycle processing that yield multiple protein products, as compared to most plant-based products that only yield one product. Sunflower based proteins are still in the refine/optimize phase of Burcon 2.0. Burcon forecasts its opportunity in the sunflower market to be between \$215.0M to \$392.0M in USD, with an expected TAM of \$21.3B and 6.2% market CAGR.

Hempseed – Hempseed based proteins are one of the Company's newest product offerings, having become ready to scale up with over \$2.0M worth of customer interest in FY25. This product is the world's first high-purity hempseed protein isolate at 95%, as compared to hemp protein at 65%. With a neutral flavor, off-white color, and growth and processing in North America this product line began sales in the market in 1H24 on a capital-light model. Burcon forecasts its opportunity in the hempseed market to be between \$68.0M to \$113.0M in USD, with an expected TAM of \$6.4B and 6.2% market CAGR.

Exhibit 3: Proprietary Plant Technology Platform




Source: Company Presentation

Growth Drivers

Growth drivers are led by the Burcon 2.0 initiative that is driven by best in class proteins and a go to market strategy based on a capital light model that opens new avenues for revenue capture. Historically the Company drove revenue via a royalty model where Burcon would develop products and earn royalties on those licensed products. Going forward Burcon 2.0 is expected to be more deliberate in its product development by gaining more control over the manufacturing process and by doing more commercial validation and market testing. This is expected to increase the value proposition that Burcon brings to its customers, thus allowing for the potential to partner with clients and/or sell the technology along with the option to pursue the traditional royalty model.


Exhibit 4: Capital Light Business Model



Source: Company Presentation

This is best exemplified by Burcon's partnership with HPS Food and Ingredients. This partnership gives BU access to a global network of customers as well as access to growers and raw materials. This has led to ongoing production campaigns to meet the initial orders, allowing for a time to market that is between 9-18 months. With commercial sales announced in April of 2024, the next step for this project is increasing production to meet customer demand. We expect the Company to use a similar process for its sunflower based proteins.

Exhibit 5: Hempseed Protein Roadmap



Source: Company Presentation


In 3Q25, Burcon Nutrascience announced a successful rights offering, which raised gross proceeds of \$9.43M, marking significant growth driver for the Company. This capital infusion boosted Burcon's pro-forma cash balance to approximately \$10.0M, providing a solid financial foundation to support its strategic initiatives for the next two years. The funds will primarily be used to commercialize and scale the production of Burcon's innovative plant-based protein products, as well as to fulfill obligations under the Manufacturing Agreement with ProMan. This enhanced financial position not only underscores investor confidence in Burcon's growth trajectory but also enables the company to seize upcoming market opportunities, drive product innovation, and achieve long-term profitability.

Market Overview

The plant protein market has seen drastic growth over the past several years as consumer habits have begun to change from consuming all their protein from meat-based sources to seeking out alternatives. Consumers originally shifted from traditional meat-based proteins due to concerns about the treatment of animals used to satisfy demand for meat and dairy products. However, the recent wave of demand in plant-based products has been from a younger generation that is focused on healthier eating habits and reducing environmental impacts. The rise of the vegan population is a key factor contributing to overall growth in plant protein demand as vegan diets tend to be higher in several nutritional categories such as potassium, Magnesium, and vitamins A, C, and E.

In addition to vegan and vegetarian consumers, there is also an increase in the number of consumers who are simply looking to supplement their protein consumption with a healthier, more sustainable alternative. These flexitarians are individuals that do not have specific dietary restrictions and do not entirely cut meat or dairy out of their diet, but instead make a conscious effort to replace some traditional

Exhibit 6: U.S. Plant-Based Milk Market



Source: Good Food Institute 2023 State of the Industry Report

proteins with plant proteins. In fact, according to a Numerator analysis, 38% of flexitarians said they purchase items for their nutritional benefits. Additionally, plant-based milk made up 15% of dollar milk sales in 2023 per GFI. We believe these are durable trends that complement the Company's primary markets of dairy alternatives and plant-based beverages. These products are well suited to utilize the high protein content and mild flavors found in Burcon's portfolio.

The overall plant-based protein market is anticipated to grow rapidly over the next few years with Markets and Markets projecting that the market will grow at a 14% CAGR to reach \$40.6B by 2025. The growth in the market is being driven not only by consumer preferences, but also by developments in technology that improve plant proteins taste and function for consumers. Improvements in the extraction and production of plant proteins are making consumers more open to trying plant-based proteins and meat substitutes.

Risks

Intense Competition - Given the rise to plant-based protein popularity, the Company will face significant competition in these markets. Many of these competitors have much greater manufacturing capacity and financial backing. Burcon may need to invest additional capital into its current plant to match the capacity and costs of larger producers.

Regulatory restrictions - Burcon is governed by regulatory regimes that determine its ability to sell food ingredients in the United States and Canada. Burcon will need to obtain the necessary permitting and licensing to produce these ingredients and keep up with these regulations. Any change in the laws or the Company's inability to adhere to these regulations will inhibit the Company's ability to produce and sell its products.

Patents and IP rights - Burcon's success in generating further revenue depends on its ability to retain its intellectual property for its extraction of proteins. If Burcon is not able to protect its intellectual property through ruling of the courts or inability to retain the necessary counsel, revenue growth could be significantly reduced. In addition, costs associated with such litigation could reduce profits and cash flow.

Dependent on agriculture yields - Burcon's products are affected by crop yields and if crop yields decline in a certain season, those input costs would increase for the Company. Increases in these input costs would negatively affect profits or need to be passed on to the consumer.

Valuation Summary

We are using a Discounted Cash Flow analysis to help arrive at a valuation range for Burcon. As Burcon is currently the only public pure play alternative protein manufacturer, multiple analysis is difficult. Furthermore, the Company has strong growth upside, which does not lend itself to the low steady growth of grain processors. Additionally, the Company is much smaller and more illiquid than most other food ingredient companies. We have included a comps analysis table to frame a range where Burcon could be trading when earnings and EBITDA become positive, however, as shown by our income statement forecast, we expect the Company to become cash flow positive before then which gives us the confidence needed to use a DCF analysis.

Comparative Analysis
(all figures in M, except per share information)

Company Name	Symbol	Price ⁽¹⁾	Mrkt Cap	EV	BV/Share	EV/Revenue ^(2,3)			EV/EBITDA ^(2,3)			P/E ^(2,3)		
						2024	2025E	2026E	2024	2025E	2026E	2024	2025E	2026E
Beyond Meat, Inc.	BYND	\$ 1.11	\$ 479.3	\$ 1,673.6	\$ (10.22)	4.13x	6.03x	6.06x	-10.7x	-14.7x	-25.6x	-1.5x	-0.6x	-0.8x
The Hain Celestial Group, Inc.	HAIN	\$ 1.42	\$ 115.0	\$ 844.9	\$ 4.93	0.79x	0.56x	0.56x	10.3x	8.3x	6.9x	-3.2x	35.5x	7.5x
Hormel Foods Corporation	HRL	\$ 22.27	\$ 12,380.5	\$ 14,616.5	\$ 14.70	1.64x	1.19x	1.16x	14.8x	11.5x	10.8x	22.7x	16.6x	14.7x
Kellanova	K	\$ 83.36	\$ 28,989.7	\$ 35,067.7	\$ 12.08	2.66x	2.75x	2.69x	13.9x	15.7x	15.2x	20.7x	22.5x	21.9x
The Kraft Heinz Company	KHC	\$ 24.77	\$ 29,200.8	\$ 47,387.8	\$ 35.01	2.17x	1.90x	1.89x	8.7x	8.3x	8.3x	13.5x	9.8x	9.8x
The Simply Good Foods Company	SMPL	\$ 19.63	\$ 1,901.3	\$ 2,107.3	\$ 18.12	3.11x	1.46x	1.44x	16.4x	8.1x	7.6x	27.5x	11.0x	10.0x
Tyson Foods, Inc.	TSN	\$ 54.02	\$ 19,598.0	\$ 28,089.0	\$ 51.23	0.55x	0.51x	0.50x	8.6x	7.9x	8.1x	19.3x	13.7x	13.3x
Vital Farms, Inc.	VITL	\$ 32.53	\$ 1,471.7	\$ 1,383.0	\$ 7.40	2.49x	1.78x	1.48x	19.7x	11.9x	10.3x	30.3x	22.0x	19.5x
Average						\$ 16.66	2.2x	2.0x	2.0x	10.2x	7.1x	5.2x	16.2x	16.3x
Median						\$ 13.39	2.3x	1.6x	1.5x	12.1x	8.3x	8.2x	20.0x	15.2x
Burcon NutraScience Corpora	BU	\$ 1.64	\$ 20.7	\$ 33.6	\$ 0.21	50.7x	27.0x	4.4x	N/A	N/A	30.8x	N/A	N/A	99.0x

(1) Previous day's closing price

(2) Estimates are from Capital IQ

(3) Forward estimates as of calendar year

(4) All Values in USD at an exchange rate of \$1.40 CAD/USD

Source: Company reports, CapitalIQ, Stonegate Capital Partners

Our DCF analysis relies on a range of discount rates between 10.50% and 11.00% with a midpoint of 10.75%, which we believe accurately accounts for the size and relative illiquidity of BU. This arrives at a valuation range of \$20.29 to \$25.66 with a mid-point of \$22.61.

Sensitivity Analysis:

		Terminal Growth Rates				
		0%	1%	2%	3%	4%
Discount rate	10.25%	\$21.22	\$22.68	\$24.51	\$26.84	\$29.91
	10.50%	\$20.48	\$21.84	\$23.53	\$25.67	\$28.46
	10.75%	\$19.78	\$21.05	\$22.61	\$24.58	\$27.13
	11.00%	\$19.11	\$20.30	\$21.75	\$23.56	\$25.89
	11.25%	\$18.47	\$19.58	\$20.93	\$22.60	\$24.74

DISCOUNTED CASH FLOW

Burcon NutraScience Corporation														
Discounted Cash Flow Model														
(in \$M, except per share)														
Estimates:	2024	2025	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E	2035E	2036E	Terminal Value
Revenue	0.2	0.4	3.2	14.0	28.2	40.9	51.1	57.5	63.2	68.0	72.2	76.4	80.2	
Operating Income	(7.0)	(7.7)	(6.3)	3.5	7.1	18.4	31.2	38.5	42.4	49.0	52.0	57.3	60.2	
Less: Taxes (benefit)	-	-	0.0	-	1.4	4.6	7.8	9.6	10.6	12.2	13.0	14.3	15.0	
NOPAT	(7.0)	(7.7)	(6.4)	3.5	5.6	13.8	23.4	28.9	31.8	36.7	39.0	43.0	45.1	
Plus: Depreciation & Amortization	0.7	0.8	1.0	1.0	1.1	1.2	1.3	1.3	1.2	1.3	1.4	1.5	1.6	
Plus: Changes in WC	(2.6)	(0.0)	(0.0)	(0.1)	(0.1)	(0.2)	(0.3)	(0.3)	(0.3)	(0.3)	(0.4)	(0.4)	(0.4)	
Less: Capex	(0.1)	(0.1)	(0.2)	(0.7)	(0.7)	(0.9)	(1.2)	(1.3)	(1.3)	(1.4)	(1.5)	(1.6)	(1.7)	
Free Cash Flow	(9.0)	(7.0)	(5.5)	3.8	5.9	13.9	23.3	28.6	31.3	36.2	38.5	42.5	44.6	520.3
Discount period - months			6	18	30	42	54	66	78	90	102	114	126	
Discount period - years			0.5	1.5	2.5	3.5	4.5	5.5	6.5	7.5	8.5	9.5	10.5	
Discount factor			0.95	0.86	0.77	0.70	0.63	0.57	0.51	0.46	0.42	0.38	0.34	
PV of FCF			(5.3)	3.2	4.6	9.7	14.7	16.3	16.1	16.9	16.2	16.1	15.3	178.1
Growth rate assumptions:														
Revenue		107%	738.9%	337.7%	101.4%	45.1%	24.9%	12.5%	10.0%	7.5%	6.2%	5.8%	5.0%	
Operating Income		9.7%	-17.8%	nm	99.3%	161.2%	69.3%	23.6%	10.0%	15.5%	6.2%	10.2%	5.0%	
EBITDA		9.2%	-22.8%	nm	79.6%	140.7%	65.6%	22.6%	9.4%	15.3%	6.2%	10.1%	5.0%	
Free Cash Flow		-23.0%	-20.4%	nm	56.5%	135.2%	67.7%	23.1%	9.5%	15.7%	6.3%	10.3%	5.1%	
Margin assumptions:														
Operating Income	nm	nm	-197.8%	25.3%	25.0%	45.0%	61.0%	67.0%	67.0%	72.0%	72.0%	75.0%	75.0%	
D&A as a % of sales	380.1%	210.0%	31.3%	7.1%	3.9%	2.9%	2.5%	2.3%	1.9%	1.9%	1.9%	2.0%	2.0%	
EBITDA	nm	-1809%	-166.5%	32.4%	28.9%	47.9%	63.5%	69.3%	68.9%	73.9%	73.9%	77.0%	77.0%	
Taxes	0.0%	0.0%	-0.5%	0.0%	20.0%	25.0%	25.0%	25.0%	25.0%	25.0%	25.0%	25.0%	25.0%	
Changes in WC	nm	-0.5%	-0.5%	-0.5%	-0.5%	-0.5%	-0.5%	-0.5%	-0.5%	-0.5%	-0.5%	-0.5%	-0.5%	
Capex as a % of sales	-68.9%	-15.0%	-5.0%	-5.0%	-2.5%	-2.3%	-2.3%	-2.3%	-2.1%	-2.1%	-2.1%	-2.1%	-2.1%	
Valuation:														
Shares outstanding	12.7													
PV of FCF	123.8													
PV of Terminal Value	178.1													
Enterprise Value	301.9													
less: Net Debt	15.0													
Estimated Total Value:	286.9													
Est Equity Value/share:	\$22.61													
Sensitivity Analysis:														
Discount rate	Terminal Growth Rates													
		0%	1%	2%	3%	4%								
	10.25%	\$21.22	\$22.68	\$24.51	\$26.84	\$29.91								
	10.50%	\$20.48	\$21.84	\$23.53	\$25.67	\$28.46								
	10.75%	\$19.78	\$21.05	\$22.61	\$24.58	\$27.13								
	11.00%	\$19.11	\$20.30	\$21.75	\$23.56	\$25.89								
11.25%	\$18.47	\$19.58	\$20.93	\$22.60	\$24.74									
Price	\$2.29													

Source: Company Reports; Stonegate Capital Markets

BALANCE SHEET

Burcon NutraScience Corporation
Consolidated Balance Sheets (CAD\$ M)
Fiscal Year End: March

						Q1	Q2	Q3	Q4		Q1	Q2	Q3	Q4		Q1	Q2
ASSETS	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	Jun-23	Sep-23	Dec-23	Mar-24	FY 2024	Jun-24	Sep-24	Dec-24	Mar-25	FY 2025E	Jun-25	Sep-25
Cash and Equivalents	0.5	15.0	14.0	7.0	1.5	3.6	2.2	0.7	4.2	4.2	2.2	1.0	0.6	7.3	7.3	4.2	1.8
Restricted Cash	-	-	-	0.1	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts Receivable	0.1	0.3	0.3	0.2	0.3	0.2	0.2	0.1	0.6	0.6	0.4	0.3	0.0	0.1	0.1	0.5	0.4
Inventory	-	0.1	0.1	-	-	-	-	-	0.1	0.1	0.0	0.2	0.2	0.2	0.2	0.4	0.5
Prepaid Expenses	0.3	0.3	0.2	0.3	0.1	0.1	0.2	0.3	0.3	0.3	0.5	0.5	0.3	0.2	0.2	0.2	0.2
Total Current Assets	0.9	15.8	14.6	7.6	1.9	3.9	2.6	1.1	5.2	5.2	3.1	2.0	1.2	7.8	7.8	5.4	2.8
Property, plant and equipment	0.3	0.5	1.0	0.9	1.0	0.9	0.9	0.9	0.8	0.8	1.0	1.1	1.0	1.0	1.0	1.1	1.6
Right of Use Assets	-	-	-	-	-	-	-	-	0.3	0.3	-	-	-	14.8	14.8	13.5	13.3
Deferred Development Costs	-	1.6	4.5	6.2	5.8	5.7	5.6	5.5	5.4	5.4	5.3	5.2	5.1	5.0	5.0	4.8	4.7
Investment in Merit Functional Foods Corporation	-	12.2	16.4	13.4	-	-	-	-	-	-	-	-	-	-	-	-	-
Goodwill	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
Other long term assets	-	-	-	-	-	-	-	-	-	-	-	-	-	0.9	0.9	0.8	0.9
Total Assets	2.5	31.3	37.7	29.3	9.9	11.8	10.4	8.7	12.9	12.9	10.6	9.6	8.5	30.7	30.7	27.0	24.5
LIABILITIES AND SHAREHOLDERS' EQUITY																	
Accounts Payable and accrued liabilities	0.6	1.1	1.4	0.9	0.6	0.7	0.6	0.6	0.8	0.8	0.5	0.9	0.7	1.3	1.3	1.1	1.2
Short Term Borrowings	1.3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Derivative Liability	0.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Convertible Notes	-	0.3	-	0.1	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	2.0	-	-	-	-	-	-	-	0.3	0.3	-	0.2	0.1	0.0	0.0	0.0	-
Lease Liability	-	-	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.0	0.0	0.0	0.9	0.9	1.2	1.5
Accrued Interest	0.6	0.2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Current Portion of Secured Loan	-	-	-	-	-	-	-	-	-	-	-	-	2.0	2.1	2.1	2.1	8.2
Total Current Liabilities	4.4	1.6	1.4	1.0	0.6	0.7	0.6	0.7	1.4	1.4	0.5	1.1	2.9	4.3	4.3	4.4	11.0
Convertible Notes	-	6.7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Secured Loans	-	-	-	-	5.1	5.2	5.2	5.3	6.4	6.4	6.5	6.7	5.7	5.8	5.8	5.9	-
Lease Liability	-	-	0.0	0.1	0.0	0.0	-	-	-	-	-	0.1	0.1	13.6	13.6	13.0	13.4
Total Liabilities	4.4	8.3	1.5	1.1	5.8	6.0	5.8	6.0	7.8	7.8	7.1	7.9	8.6	23.7	23.7	23.4	24.4
Capital Stock	73.4	98.0	114.1	114.6	114.6	117.7	117.7	117.8	122.1	122.1	122.1	122.2	122.3	131.6	131.6	131.6	131.6
Contributed Surplus	9.0	9.0	14.1	15.9	16.8	16.8	16.9	17.3	17.3	17.3	17.4	17.4	18.8	19.2	19.2	19.2	19.7
Options	9.2	9.7	6.5	7.0	7.3	7.4	7.5	7.3	7.4	7.4	7.4	7.4	6.1	5.7	5.7	5.9	5.5
Warrants	0.2	1.8	0.6	-	-	0.2	0.2	0.2	0.2	0.2	0.3	0.7	0.7	0.7	0.7	0.7	0.7
Convertible debentures	-	2.8	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restricted Share Units	-	-	-	0.0	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.0	0.0	0.0	0.0
Foreign Currency Translation Reserve	-	-	-	-	-	-	-	-	-	-	-	-	-	0.0	0.0	0.0	(0.0)
Deficit	(93.7)	(98.4)	(99.0)	(109.2)	(134.6)	(136.5)	(137.9)	(140.0)	(142.0)	(142.0)	(143.9)	(146.3)	(148.1)	(150.3)	(150.3)	(153.8)	(157.4)
Total Consolidated Equity	(2.0)	22.9	36.3	28.2	4.1	5.8	4.6	2.8	5.2	5.2	3.5	1.7	(0.1)	6.9	6.9	3.6	0.1
Total Liabilities and Shareholders' Equity	2.5	31.3	37.7	29.3	9.9	11.8	10.4	8.7	12.9	12.9	10.6	9.6	8.5	30.7	30.7	27.0	24.5

Source: Company Reports, Stonegate Capital Partners

INCOME STATEMENT

Burcon NutraScience Corporation																					
Consolidated Statements of Income (in CAD\$ M, except per share amounts)																					
Fiscal Year End: March																					
	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	Q1 Jun-24	Q2 Sep-24	Q3 Dec-24	Q4 Mar-25	FY 2025E	Q1 Jun-25	Q2 Sep-25	Q3 E Dec-25	Q4 E Mar-26	FY 2026E	Q1 E Jun-26	Q2 E Sep-26	Q3 E Dec-26	Q4 E Mar-27	FY 2027E	
Royalty Income	\$ 0.0	\$ 0.0	\$ 0.2	\$ 0.4	\$ 0.2	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 0.1	\$ 0.1	\$ 0.1	\$ 0.3	\$ 0.3	\$ 0.5	\$ 1.1	
Product Income	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 0.2	\$ 0.0	\$ 0.1	\$ 0.0	\$ 0.4	\$ 0.3	\$ 0.4	\$ 1.0	\$ 1.4	\$ 3.1	\$ 2.3	\$ 2.9	\$ 3.5	\$ 4.2	\$ 12.9	
Research Income	-	0.3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Total Revenues	0.0	0.3	0.2	0.4	0.2	0.2	0.0	0.1	0.0	0.4	0.3	0.4	1.0	1.5	3.2	2.4	3.2	3.7	4.7	14.0	
Cost of Goods Sold	-	-	-	-	-	0.2	0.2	0.3	0.6	1.3	1.8	2.1	0.5	0.7	5.0	1.1	1.4	1.6	1.9	5.9	
Gross Profit	0.0	0.3	0.2	0.4	0.2	0.0	(0.1)	(0.2)	(0.5)	(0.9)	(1.4)	(1.7)	0.5	0.8	(1.8)	1.3	1.8	2.1	2.8	8.1	
Research and Development	0.7	0.4	3.3	4.1	3.6	0.7	1.2	0.7	0.5	3.0	0.3	0.4	0.4	0.4	1.5	0.4	0.5	0.5	0.5	1.8	
Intellectual Property	0.8	0.8	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
G&A	2.1	3.7	4.3	3.8	3.6	1.1	0.9	0.9	0.9	3.8	0.7	0.8	0.8	0.8	3.0	0.7	0.7	0.7	0.7	2.8	
Total Operating Expenses	3.7	4.9	7.6	7.9	7.2	1.8	2.1	1.6	1.4	6.8	1.0	1.2	1.2	1.2	4.5	1.1	1.2	1.2	1.2	4.6	
Operating Income	(3.6)	(4.6)	(7.4)	(7.5)	(7.0)	(1.8)	(2.2)	(1.8)	(1.9)	(7.7)	(2.5)	(2.9)	(0.6)	(0.3)	(6.3)	0.2	0.7	1.0	1.7	3.5	
Warrant Valuation Adjustment	(0.1)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Interest and Other Income	(0.3)	(0.3)	0.4	(0.1)	(0.4)	(0.1)	(0.1)	(0.0)	(0.3)	(0.6)	0.1	(0.8)	0.1	0.1	(0.5)	0.2	0.2	0.2	0.2	0.8	
Management Fee Income	0.4	0.3	0.1	0.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Merit (Loss) Gain	(0.9)	(2.4)	(4.3)	(5.5)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Foreign Exchange (Loss) Gain	0.0	(0.0)	(0.0)	0.0	(0.0)	0.0	(0.0)	0.0	0.0	0.0	(0.3)	0.1	0.0	0.0	(0.1)	0.0	0.0	0.0	0.0	0.1	
Other Gain (Loss)	(0.0)	6.4	1.0	(12.3)	-	-	-	-	-	-	(0.8)	-	-	-	(0.8)	-	-	-	-	-	
Change in Fair Value of Derivative Liability	0.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Profit Before Taxes	(4.6)	(0.6)	(10.3)	(25.4)	(7.4)	(1.9)	(2.4)	(1.8)	(2.3)	(8.3)	(3.5)	(3.6)	(0.5)	(0.2)	(7.8)	0.4	0.9	1.2	1.9	4.5	
Provision for Income Tax & Other	-	-	-	-	-	-	-	-	-	-	-	0.0	-	-	0.0	-	-	-	-	-	
Net Income	(4.6)	(0.6)	(10.3)	(25.4)	(7.4)	(1.9)	(2.4)	(1.8)	(2.3)	(8.3)	(3.5)	(3.6)	(0.5)	(0.2)	(7.8)	0.4	0.9	1.2	1.9	4.5	
Basic EPS	\$ (0.96)	\$ (0.11)	\$ (1.89)	\$ (4.67)	\$ (0.06)	\$ (0.01)	\$ (0.02)	\$ (0.29)	\$ (0.18)	\$ (1.06)	\$ (0.27)	\$ (0.03)	\$ (0.00)	\$ (0.00)	\$ (0.07)	\$ 0.00	\$ 0.01	\$ 0.01	\$ 0.01	\$ 0.03	
Diluted EPS	\$ (1.01)	\$ (0.11)	\$ (1.89)	\$ (4.67)	\$ (0.06)	\$ (0.01)	\$ (0.02)	\$ (0.29)	\$ (0.18)	\$ (1.06)	\$ (0.27)	\$ (0.03)	\$ (0.00)	\$ (0.00)	\$ (0.07)	\$ 0.00	\$ 0.01	\$ 0.01	\$ 0.01	\$ 0.03	
WTD Shares Out - Basic	4.8	5.4	5.4	5.4	121.4	142.1	142.2	6.1	12.7	7.8	12.7	142.2	142.2	142.2	109.8	142.3	142.3	142.3	142.3	142.3	
WTD Shares Out - Diluted	4.6	5.4	5.4	5.4	121.4	142.1	142.2	6.1	12.7	7.8	12.7	142.2	142.2	142.2	109.8	142.3	142.3	142.3	142.3	142.3	
EBITDA	(3.6)	(4.6)	(7.4)	(7.5)	(7.0)	(1.8)	(2.2)	(1.8)	(1.9)	(7.7)	(2.5)	(2.9)	(0.6)	(0.3)	(6.3)	0.2	0.7	1.0	1.7	3.5	

Source: Company Reports, Stonegate Capital Partners estimates

IMPORTANT DISCLOSURES AND DISCLAIMER

- (a) The research analyst and/or a member of the analyst's household do not have a financial interest in the debt or equity securities of the subject company.
- (b) The research analyst responsible for the preparation of this report has not received compensation that is based upon Stonegate's investment banking revenues.
- (c) Stonegate or any affiliate have not managed or co-managed a public offering of securities for the subject company in the last twelve months, received investment banking compensation from the subject company in the last 12 months, nor expects or receive or intends or seek compensation for investment banking services from the subject company in the next three months.
- (d) Stonegate's equity affiliate, Stonegate Capital Partners, "SCP" has a contractual agreement with the subject company to provide research services, investor relations support, and investor outreach. SCP receives a monthly retainer for these non-investment banking services.
- (e) Stonegate or its affiliates do not beneficially own 1% or more of any class of common equity securities of the subject company.
- (f) Stonegate does not make a market in the subject company.
- (g) The research analyst has not received any compensation from the subject company in the previous 12 months.
- (h) Stonegate, the research analyst, or associated person of Stonegate with the ability to influence the content of the research report knows or has reason to know of any material conflicts of interest at the time of publication or distribution of the research report.
- (i) No employee of Stonegate has a position as an officer or director of the subject company.

Ratings - Stonegate does not provide ratings for the covered companies.

Distribution of Ratings - Stonegate does not provide ratings for covered companies.

Price Chart - Stonegate does not have, nor has previously had, a rating for its covered companies.

Price Targets - Stonegate does not provide price targets for its covered companies. However, Stonegate does provide valuation analysis.

Regulation Analyst Certification:

I, Dave Storms, CFA, hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this report.

For Additional Information Contact:

Stonegate Capital Partners, Inc.

Dave Storms, CFA

Dave@stonegateinc.com

214-987-4121

Please note that this report was originally prepared and issued by Stonegate for distribution to their market professional and institutional investor customers. Recipients who are not market professional or institutional investor customers of Stonegate should seek the advice of their independent financial advisor prior to taking any investment decision based on this report or for any necessary explanation of its contents. The information contained herein is based on sources which we believe to be reliable but is not necessarily complete and its accuracy cannot be guaranteed. Because the objectives of individual clients may vary, this report is not to be construed as an offer or the solicitation of an offer to sell or buy the securities herein mentioned. This report is the independent work of Stonegate Capital Partners and is not to be construed as having been issued by, or in any way endorsed or guaranteed by, any issuing companies of the securities mentioned herein. The firm and/or its employees and/or its individual shareholders and/or members of their families and/or its managed funds may have positions or warrants in the securities mentioned and, before or after your receipt of this report, may make or recommend purchases and/or sales for their own accounts or for the accounts of other customers of the firm from time to time in the open market or otherwise. While we endeavor to update the information contained herein on a reasonable basis, there may be regulatory, compliance, or other reasons that prevent us from doing so. The opinions or information expressed are believed to be accurate as of the date of this report; no subsequent publication or distribution of this report shall mean or imply that any such opinions or information remains current at any time after the date of this report. All opinions are subject to change without notice, and we do not undertake to advise you of any such changes. Reproduction or redistribution of this report without the expressed written consent of Stonegate Capital Partners is prohibited. Additional information on any securities mentioned is available on request.
